Actively Recruiting
Evaluating Low Dose Mosunetuzumab Treatment for Slow-Growing B-Cell Lymphoma in Adults
Led by University of Washington · Updated on 2026-08-27
20
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating mosunetuzumab, a monoclonal antibody, in a phase II trial for patients with slow-growing indolent B-cell lymphoma. The study aims to assess the safety, side effects, and effectiveness of this treatment in patients with specific types and stages of lymphoma, including follicular and marginal zone lymphoma. The trial is sponsored by the University of Washington and focuses on patients who have not received prior lymphoma therapy. Participants receive mosunetuzumab through intravenous infusion lasting 2 to 4 hours on days 1, 8, 15, and 22. During the study, patients undergo blood sample collections and imaging tests such as PETCT scans. Additional CT or MRI scans and collection of oral or rectal swabs may be done as needed. After the treatment phase, participants are followed up at week 13, 6 months, and then monitored for up to 5 years to assess long-term outcomes. Throughout the trial, researchers collect various data including imaging results, blood tests, and questionnaires. They measure overall response to treatment by week 13 and monitor adverse events, including serious immune-related side effects, for 30 days after the last dose. Long-term outcomes such as progression-free survival, duration of response, and time to next treatment are followed for up to 5 years. This comprehensive monitoring helps understand both immediate and lasting effects of mosunetuzumab in treating indolent B-cell lymphoma.
CONDITIONS
Brief Title
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Research Team
A
Ajay Gopal
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here